MedTrace Logo

Phase 1 Single Subcutaneous Dose Study of MLN1202

NCT02426021 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2016-10-27

No results posted yet for this study

Summary

The objective of the study is to investigate the safety, pharmacokinetics, and pharmacodynamic effect of a single dose of MLN1202 in healthy Japanese male adults.

Conditions

  • Healthy Japanese and Caucasian Male Adults

Interventions

DRUG

MLN1202

Subcutaneous administration of MLN1202

DRUG

MLN1202 Placebo

Subcutaneous administration of MLN1202 placebo

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426021 on ClinicalTrials.gov